Background /Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin.
Methods Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms.
Results In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023).
Conclusions The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.
Citations
Citations to this article as recorded by
Xiaojianzhong decoction attenuates gastric mucosal injury by activating the p62/Keap1/Nrf2 signaling pathway to inhibit ferroptosis Juan Chen, Jiaxiang Zhang, Ting Chen, Shengchuan Bao, Jingtao Li, Hailiang Wei, Xin Hu, Yan Liang, Fanrong Liu, Shuguang Yan Biomedicine & Pharmacotherapy.2022; 155: 113631. CrossRef
A measure of asymmetry for ordinal square contingency tables with an application to modified LANZA score data Satoru Shinoda, Kouji Yamamoto, Kouji Tahata, Sadao Tomizawa Journal of Applied Statistics.2020; 47(7): 1251. CrossRef